课题基金 / 基金详情

METHOTREXATE AND METABOLISM IN HEPATIC CELLS

METHOTREXATE AND METABOLISM IN HEPATIC CELLS
甲氨蝶呤和肝细胞的代谢
批准号:
3167079
负责人:
JOHN H GALIVAN
金额:
$21.91万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1979
资助国家:
美国
项目状态:
已结题
起止时间:
1979-07-01 至 1995-12-31

项目摘要

项目成果

JOHN H GALIVAN的其他基金

相似基金

相关文献

中文摘要
翻译
建议的研究旨在加深理解和新颖性 接近抗叶酸的方法。我们计划评估几个决定因素 他们的临床前治疗,包括1)与 抗叶酸的谷氨酰化对肿瘤细胞和宿主的毒性2) 抗叶酸发挥细胞毒性作用的生化机制 通过细胞中叶基多谷氨酸的扰动3)生化 以及调节谷氨酰化和水解酶的药物过程 叶基和反叶基多谷氨酸盐的相互作用以及4)叶酸- 胸苷合成酶的类似抑制剂与靶酶。 在接近第一个目标的过程中,一系列的叶酸和反叶酸 合成的谷氨酸的4碳中含有氟的合成 严重尊重谷氨酰化,但不改变 分子。4-氟甲氨蝶呤已被用于显示 甲氨蝶呤不能被谷氨酰化时的活性。4-氟叶酸 将用来确定与肿瘤细胞和宿主的救援能力 组织。这一实验设计旨在确定是否有选择性 通过阻止谷氨酰化可以更有效地拯救宿主 救援人员。 一种高灵敏的叶酸辅酶测定法 我们的实验室已经对同事进行了调整和修改,以提供 5,10CH2H4PteGlun,H4PteGlun, H2PteGlun、10-HCO-H4PteGlun和10-HCOH2PteGlun是关键的叶酸 参与嘌呤和嘧啶的生物合成。我们将衡量这些指标 用甲氨蝶呤和4-甲氨蝶呤处理细胞后的物种 氟甲氨蝶呤和用叶酸和4-氟叶酸抢救。 DHFR抑制剂与炔丙基喹唑啉抑制剂的联合应用 胸苷合成酶和琼脂转化酶抑制剂5,10 二氮杂四氢叶酸将用叶酸培养的细胞进行评估 确定酸或5-甲基四氢叶酸是否大于添加剂药物 活动就会发生。尽管我们已经展示了协同作用的药物活性 在含有叶酸的混合介质中,减量使用 叶酸底物将暗示体内活性的潜力。如果 发现积极的药物相互作用,将进行机械性评估 包括对叶酸扰动的彻底分析,如 如上所述。此外,还对其进行了详细的机理分析。 将用野生型细胞进行炔丙基喹唑啉的活性 胸苷合成酶基因扩增70倍。这些调查 详细确定了对这一新类别的细胞反应 抑制剂。贯穿所有这些研究的一个主题是理解 叶基谷氨酰化和水解酶的调节机制 抗叶基多谷氨酸盐。这将在酶的水平上进行评估,通过 叶基多谷氨酸合成酶和γ-谷氨酰水解酶的研究 在细胞水平上,通过检查扰乱细胞生长速度的药物 多聚谷氨酸的形成和分解。
英文摘要
The proposed studies are directed at a deeper understanding and novel approaches to the antifolates. We plan to evaluate several determinants of their preclinical therapeutics which includes 1) the relationship of glutamylation of antifolates to tumor cytotoxicity and host toxicity 2) the biochemical mechanisms by which antifolates exert their cytotoxicity through perturbations in the cell folylpolyglutamates 3) the biochemical and pharmacological processes which regulate glutamylation and hydrolysis of folyl and antifolylpolyglutamates and 4) the interaction of the folate- analog inhibitors of thymidylate synthase with the target enzyme. In approaching the first goal a series of folates and antifolates have been synthesized containing a fluorine in the 4 carbon of glutamate which severely regards glutamylation but does not alter other properties of the molecule. 4-Fluoromethotrexate has been used to show changes in the activity of methotrexate when it can't be glutamylated. 4-Fluorofolinic will be used to determine the rescue capacity with tumor cells and host tissue. This experimental design is intended to determine if selective host rescue can be achieved more effectively by preventing glutamylation of the rescue agent. A highly sensitive assay for folate coenzymes developed by Priest and coworkers has been adapted and modified in our laboratory to give essentially quantitative recoveries of 5,10CH2H4PteGlun, H4PteGlun, H2PteGlun, 10-HCO-H4PteGlun, and 10-HCOH2PteGlun which are the key folates involved in purine and pyrimidine biosynthesis. We will measure these species following treatment of cells with methotrexate and 4- fluoromethotrexate and rescue with folinic and 4-fluorofolinic acid. Combinations of DHFR inhibitors with propargylquinazoline inhibitors of thymidylate synthase and the GAR transformylase inhibitor 5,10 dideazatetrahydrofolate will be evaluated with cells cultured in folinic acid or 5 methyltetrahydrofolate to determine if greater than additive drug activity occurs. Although we have already shown synergistic drug activity with combinations in folic acid containing medium, the use of the reduced folate substrates will suggest the potential for in vivo activity. If positive drug interactions are found, mechanistic evaluations will be undertaken including a thorough analysis of folate perturbations as described above. In addition a detailed mechanistic analysis of the activity of propargylquinazolines will be undertaken with wild type cells and those amplified 70 fold for thymidylate synthase. These investigations are directed determining in detail the cellular response to this new class of inhibitors. A theme throughout all these studies is understanding the mechanisms which regulate the glutamylation and hydrolysis of folyl and antifolyl polyglutamates. This will be evaluated at the enzymatic level by investigation of folylpolyglutamate synthetase and gamma-glutamylhydrolase and at the cellular level by examining agents which perturb the rate of polyglutamate formation and breakdown.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
WADSWORTH CTR: INFECTIOUS DIS, WEST NILE, AIDS, MALARIA, TB, BIOTERRORISM, LYME
  • 批准号:
    6794518
  • 项目类别:
  • 资助金额:
    $199.93万
  • 财政年份:
    2002
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
  • 批准号:
    3189422
  • 项目类别:
  • 资助金额:
    $8.26万
  • 财政年份:
    1988
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
  • 批准号:
    3189421
  • 项目类别:
  • 资助金额:
    $8.01万
  • 财政年份:
    1988
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
  • 批准号:
    3189420
  • 项目类别:
  • 资助金额:
    $7.99万
  • 财政年份:
    1988
  • 负责人:
    JOHN H GALIVAN
  • 依托单位:
海外基金